Pantoprazole on Insulin Secretion in Diabetes

• Status: Completed
• Trial end date: 2013-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study is to evaluate the effect of pantoprazole on insulin secretion in drug-naïve patients with type 2 diabetes.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Coordinación de Investigación en Salud, Mexico
• Treatments: Insulin; Pantoprazole

Criteria

Inclusion Criteria:

• Type 2 diabetes mellitus

• Drug-Naive

• No complications

• HbA1c 7 to < 9%

• Fasting plasma glucose < 210mg/dl

• Body mass index 30.0 to 39.9 and body weight stable for at least 3 months before the study

• Non smokers

• Blood pressure < 130/80

Exclusion Criteria:

• Diabetes complications

• Women pregnant or stage of lactation

• Hepatic, renal, autoimmune disease

• Take drugs with effects on insulin secretion

• Zollinger-Ellison disease

• Gastric or pancreatic tumor.